Yilmaz, E.Coskun, E. I.Gul, M.Sahin, N.Tuncay, G.Simsek, Y.2024-08-042024-08-0420170392-2936https://doi.org/10.12892/ejgo3471.2017https://hdl.handle.net/11616/98058Objective: Examination of the role of nuclear factor-kappa beta (NF-kappa B) expression in the etiopathogenesis of endometrial cancer, by means of the immunohistochemical method. Materials and Methods: Patients who applied to participate in the study at the clinic were grouped into three categories: those diagnosed with benign endometrial pathology, those with endometrial hyperplasia, and those with endometrial cancer. NF-kappa B analysis was conducted in the endometrial tissues of the patients' paraffin blocks by means of the immunohistochemical method. For objective assessment purposes, the H score of each patient was calculated. SP SS 15.0 program was employed for statistical analysis. Results: The average H score of the first group, comprising benign endometrial pathologies, was 102.4 +/- 85.9, that of the hyperplasia group was 143.6 +/- 122.4, and that of the cancer group was 276.8 +/- 61.8. The average values of groups 1 and 2 were similar (p = 0.349); however, the third group's average H score was significantly higher (p < 0.001). Conclusion: NF-kappa B, which is a critical mediator in the inflammation process, might be related to the development of premalign and malign endometrial changes.eninfo:eu-repo/semantics/closedAccessEndometrial cancerEndometrial hyperplasiaInflammationNF-kBNuclear factor-kappa beta pathway and endometrial cancer: a pilot studyArticle38453654010.12892/ejgo3471.20172-s2.0-85037091910N/AWOS:000406893500009Q4